Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy.
Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy; Unit of Medical Oncology, Department of Surgery and Oncology, University of Verona Hospital Trust, Verona, Italy.
Crit Rev Oncol Hematol. 2019 Nov;143:124-129. doi: 10.1016/j.critrevonc.2019.09.002. Epub 2019 Sep 9.
The role of adjuvant chemotherapy (ACT) for resected biliary tract cancer (BTC) is still unclear and there is no specific recommendation by international guidelines.
To perform a meta-analysis of randomized clinical trials (RCTs) to better define the clinical benefit and risks of ACT or observation in resected BTC.
A systematic literature search of Pubmed, Embase, and the Cochrane Library was performed up to April 2019. A meta-analysis was carried out using the random effects model.
ACT provided a mild improvement in recurrence free survival (RFS) (HR:0.83, 95%CI 0.69-0.99) and no effect on overall survival (OS) (HR:0.91, 95%CI 0.75-1.09). Similarly, ACT showed no effect on OS in lymph-node positive subgroup (HR:0.84, 95% CI 0.65-1.08) and surgical margin positive subgroup (HR:0.95, 95%CI 0.69-1.31). Moreover, ACT led to a substantial increase of chemotherapy-associated adverse events (RR:3.03, 95%CI 2.22-4.15).
ACT for resected BTC patients modestly improved RFS with no effect on OS and a substantial increase in chemotherapy associated AEs.
辅助化疗(ACT)在可切除胆道癌(BTC)中的作用仍不清楚,国际指南也没有具体推荐。
对随机临床试验(RCT)进行荟萃分析,以更好地确定 ACT 或观察在可切除 BTC 中的临床获益和风险。
对 Pubmed、Embase 和 Cochrane 图书馆进行了系统的文献检索,检索时间截至 2019 年 4 月。使用随机效应模型进行荟萃分析。
ACT 可轻度改善无复发生存率(RFS)(HR:0.83,95%CI 0.69-0.99),但对总生存期(OS)无影响(HR:0.91,95%CI 0.75-1.09)。同样,ACT 对淋巴结阳性亚组(HR:0.84,95%CI 0.65-1.08)和手术切缘阳性亚组(HR:0.95,95%CI 0.69-1.31)的 OS 也没有影响。此外,ACT 导致化疗相关不良事件显著增加(RR:3.03,95%CI 2.22-4.15)。
ACT 可适度改善可切除 BTC 患者的 RFS,对 OS 无影响,但与化疗相关的 AEs 显著增加。